O T C
PAOG Signs Clinical Research Organization (CRO) To Advance Respiratory Cannabis Treatment Through Regulatory Approval

Sandusky, OH – October 23, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG signed the agreement yesterday,

PAOG Advances FDA Application Process For Respiratory Cannabis Drug Treatment

Sandusky, OH – October 20, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG announced last week

PAOG and PURA Announce Free Hemp Seed Giveaway To Promote CBD and Hemp Awareness

Sandusky, OH – October 16, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) and Puration, Inc. (OTC PINK: PURA) today announced a free hemp seed giveaway in conjunction with the recent partnership between the two companies where PAOG will be building a hemp cultivation facility on PURA’s Farmersville, Texas property.  

PAOG Releases Cannabis Drug Development Update

Sandusky, OH – October 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG anticipates entering into an agreement with a contract research organization (CRO) within

PAOG CEO Jim DiPrima Answers Questions About Cannabis Investigational New Drug Application Plans With FDA

Sandusky, OH – October 2, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses recent news regarding PAOG’s latest moves to engage a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food

PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech To Prepare RespRx For IND

Sandusky, OH – October 1, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging

PAOG Cannabis Pharmaceutical Research Initiative Gains New Traction

Sandusky, OH – September 30, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today indicated plans to reveal new information on the company’s initiative to expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD). In a media interview scheduled for release on Friday, October

PAOG Completes Compliance Updates In Conjunction With Cannabis Biopharma Revitalization Initiative

Sandusky, OH – August 27, 2020 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced having published all required filings necessary to meet the OTC Markets “Current Information” reporting standard. Yesterday, the company published the final compliance requirement, a legal opinion, following the publications of its Q1 2020 and Q2 2020

PURA Updates 2020 100% Revenue Growth Outlook With New Dividend Information

Dallas, TX – May 22, 2020 – Puration, Inc. (OTC PINK: PURA) today released a management update to highlight notable details regarding the company’s Q1 2020 financial report published earlier this week on Wednesday, May 20, 2020. The company’s revenue for the first quarter of 2020 increased 173% to $805,000 compared to the same period

KALY Previews Investment Commitment Into Its Cannabis Biopharmaceutical Technology

Dallas, TX – February 3, 2020 – Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC PINK: KALY) (“KALY”) today previewed a letter of intent (LOI) executed with a third-party investor. The LOI details are anticipated to be released tomorrow. Management indicates the two-stage investment is of substantial magnitude and can meaningfully advance the company’s ongoing development

Contact Us

  • 707-OTC-WIRE (707-682-9473)
  • cs@otcprwire.com

All Rights Reserved © 2019